Clinical trials: Liver Tumour
Hepatocellular Carcinoma
SBRT or TACE for Advanced HCC
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in locally advanced hepatocellular carcinoma.
- Trial name
- NCT03338647
- Testing
- DEB, SBRT
- Where
- India
- Volunteers
- 180 people
- Sponsor
- University of Aarhus
Angiosarcoma
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
The purpose of this study is to test the feasibility of identifying incident cases of angiosarcoma of the liver from the network NetSarc.
- Trial name
- ANGIHE (NCT01786889)
- Testing
- blood and urine, Questionnaire, Telephone interview
- Where
- 12 sites in France
- Volunteers
- 9 people
- Sponsor
- Centre Oscar Lambret
Hepatocellular Carcinoma
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma
- Trial name
- NCT00423306
- Testing
- Darinaparsin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Alaunos Therapeutics
Colon Cancer, Rectal Cancer
Magnetic Resonance Study of Liver in Chemotherapy
The purpose of this study is to see whether magnetic resonance (MR) techniques can detect changes caused by chemotherapy in the livers of patients who have been treated for colorectal cancer.
- Trial name
- NCT00578838
- Testing
- Magnetic Resonance
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Liver Metastasis Colon Cancer
Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant
The hypothesis is that liver venous deprivation (LVD) could strongly improve hypertrophy of the future remnant liver (FRL) at 3 weeks, as compared to portal vein embolization (PVE) in patient with liver metastases from…
- Trial name
- HYPER-LIV01 (NCT03841305)
- Testing
- Liver preparation before major hepatectomy
- Where
- 12 sites in France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Montpellier
Primary Liver Cancer
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.
- Trial name
- NCT03178929
- Testing
- S-Adenosyl Methionine
- Volunteers
- 207 people
- Sponsor
- Beijing Insight Science & Technology Co. Ltd.
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC)
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
Primary liver cancer, mainly including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), represents the third leading cause of cancer-related mortality.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Primary Liver Cancer
- Trial name
- NCT07101237
- Testing
- Multi-modal ultrasonic imaging system for liver cancer
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Peking Union Medical College Hospital
Head and Neck Cancer, Urologic Cancer
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma.
- Conditions
- Head and Neck Cancer, Urologic Cancer, Lung Cancer, Breast Cancer
- Trial name
- FUTURE (NCT06827639)
- Testing
- blood collection, tissue specimen collection
- Where
- France
- Volunteers
- 640 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Hepatocellular Carcinoma
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
This study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd…
- Trial name
- NCT05441475
- Testing
- ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg, ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver.
- Conditions
- Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04175912
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 419 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Extranodal NK-T-Cell
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F- FDG PET/CT and predict disease progression during chemotherapy or survival in…
- Trial name
- NCT03051542
- Testing
- 18F-FDG PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Liver Metastasis Colon Cancer
Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cm
Preoperative chemotherapy is often used for patients with colorectal cancer liver metastasis (CLM). Many small CLMs (<=2cm) may disappear after chemotherapy, while most of these are still alive.
- Trial name
- NCT04686942
- Testing
- After sonazoid
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, HCC
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness…
- Trial name
- NCT01871545
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Colorectal Cancer
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
To evaluate the efficacy and safety of the combination regimen of Icaritin with bevacizumab + FOLFIRI in patients with liver metastases from advanced colorectal cancer.
- Trial name
- NCT06269445
- Testing
- Icaritin Combined With Bevacizumab and FOLFIRI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sir Run Run Shaw Hospital
Hepatocellular Carcinoma
The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment
The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated…
- Trial name
- NCT04299919
- Testing
- Minimally invasive treatment, Hepatectomy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Carcinoma, Hepatocellular
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
This is a Phase II study of single agent ABC294640. Patients with advanced hepatocellular carcinoma (HCC) who have experienced tumor progression or unacceptable toxicity on single agent sorafenib will receive ABC294640 500 mg by…
- Trial name
- NCT02939807
- Testing
- ABC294640
- Where
- United States
- Sponsor
- Medical University of South Carolina
Liver Neoplasm
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is commonly treated with transarterial locoregional therapies (transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)).
- Trial name
- NCT04702230
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- University of Zurich
Metastatic Breast Cancer in the Liver
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and…
- Trial name
- DELUMA (NCT06875128)
- Testing
- Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- Where
- 8 sites in United States, Italy and 2 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.